Sanofi presents study data at American Diabetes Association’s 71st Scientific Sessions
PARIS — A new study indicated that two insulin products made by French drug maker Sanofi lower blood-glucose levels to a greater extent than premixed insulin, and with improvements in quality of life and less hypoglycemia.
Sanofi announced results of the 60-week study, which compared regimens, including Lantus (insulin glargine [rDNA origin]) and Apidra (insulin glulisine [rDNA origin]).
“Optimization of insulin dosage with glargine plus a single mealtime injection of glulisine allowed more patients to reach target A1C levels than with twice-daily premixed insulin, and with less hypoglycemia,” Oregon Health and Science University section head for diabetes and study investigator Matthew Riddle said. “These findings support a stepwise approach to addition of mealtime insulin when basal insulin with oral agents is not sufficient to maintain control.”
Three analyses of data from the study were published or presented at the American Diabetes Association’s 71st Scientific Sessions in San Diego.
Lilly announces multimillion dollar investment in biotechnology
WASHINGTON — Eli Lilly will invest funds into its existing biotechnology capabilities to further research and development of multispecific therapeutics.
"In many therapeutic areas — for instance, diabetes and oncology — one medicine isn’t enough for patients to manage their disease," Lilly VP biotechnology discovery research Tom Bumol said. "With our extensive biologics experience, we can now engineer new therapies where one medicine essentially provides the benefit of two. This could produce real benefits for patients, healthcare professionals and payers."
The drug maker announced the multimillion dollar investment at the BIO International Convention in Washington, D.C.
"We are building on our strong and successful biotechnology platform, which has delivered an exciting mid- to late-stage biotechnology pipeline," said Jan Lundberg, Lilly’s EVP science and technology, and president of Lilly Research Labs. "Our further investment in multispecific therapeutics underscores Lilly’s commitment to the field of biotechnology and its importance to providing improved outcomes for individual patients."
Hi-Tech Pharmacal acquires rights to branded drugs
AMITYVILLE, N.Y. — Generic drug maker Hi-Tech Pharmacal said that it has acquired marketing and distribution rights to pain treatments made by Atley Pharmaceuticals.
Hi-Tech, which paid $3.6 million in cash for rights to the products and inventory, said some of Atley’s drugs already have been approved by the Food and Drug Administration, while others were pending approval. The company didn’t say which products it was acquiring the rights to, but noted that Hi-Tech subsidiary ECR Pharmaceuticals will produce and promote the products.
"We are pleased to add these branded prescription products to our product portfolio," Hi-Tech president and CEO David Seltzer said. "We believe the acquisition of these products creates an excellent synergy with ECR’s current product line and provides additional therapeutic options to help primary care physicians and their patients address problems with pain."